Gut microbiota of preterm infants supplemented with probiotics: sub-study of the ProPrems trial

BMC Microbiology

Gerald L. Murray¹  Dieter M. Bulach²  Erica L. Plummer³  Susan E. Jacobs⁴  Sepehr N. Tabrizi⁵ 

[1] Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Australia;Murdoch Childrens Research Institute, The Royal Childrens Hospital, Parkville, Australia;The Royal Womens Hospital, Parkville, Australia;The University of Melbourne, Parkville, Australia;Victorian Life Sciences Computation Initiative, The University of Melbourne, Carlton, Australia

关键词: Probiotics;    Very preterm infants;    Gut microbiota;    Necrotizing enterocolitis;   

DOI  :  10.1186/s12866-018-1326-1

学科分类：微生物学和免疫学

来源: BioMed Central

【 摘 要 】

The ProPrems trial, a multi-center, double-blind, placebo-controlled randomized trial, previously reported a 54% reduction in necrotizing enterocolitis (NEC) of Bell stage 2 or more from 4.4 to 2.0% in 1099 infants born before 32 completed weeks’ gestation and weighing < 1500 g, receiving probiotic supplementation (with Bifidobacterium longum subsp. infantis BB-02, Streptococcus thermophilus TH-4 and Bifidobacterium animalis subsp. lactis BB-12). This sub-study investigated the effect of probiotic supplementation on the gut microbiota in a cohort of very preterm infants in ProPrems. Bifidobacterium was found in higher abundance in infants who received the probiotics (AOR 17.22; 95% CI, 3.49–84.99, p < 0.001) as compared to the placebo group, and Enterococcus was reduced in infants receiving the probiotic during the supplementation period (AOR 0.27; 95% CI, 0.09–0.82, p = 0.02). Probiotic supplementation with BB-02, TH-4 and BB-12 from soon after birth increased the abundance of Bifidobacterium in the gut microbiota of very preterm infants. Increased abundance of Bifidobacterium soon after birth may be associated with reducing the risk of NEC in very preterm infants.

【 授权许可】

CC BY